ClinicalTrials.gg
CompletedNCT06924320Updated Nov 2, 2026

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

A Phase 1/2 interventional study of MET233 and MET097 and Placebo in Obesity and Obesity-related Medical Conditions, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Updated Nov 2, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing berobenatide in Obesity — 11 open to participants now, 15 under way, 12 of them phase 3. berobenatide · Obesity.

Enrollment
13th of 21
201 · median 258
Started
2025
with 3 others
Phase 1/2
2 of 21
none open now
Registered
4th of 21
by date
Lead sponsor
20 of 21
Pfizer

Among the 21 studies testing berobenatide in Obesity, this one is the 13th largest by enrollment, is one of 4 that started in 2025, is one of 2 in phase 1/2, and was the 4th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 21 studies testing berobenatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About berobenatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing berobenatide in Obesity, or all of them as a file.
02

Study summary

This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.

Read the detailed description

This is a randomized, placebo-controlled, double-blind, double-dummy study to investigate the safety, tolerability, PK, and PD of subcutaneous (SC) doses of MET233 co-administered with MET097 in adult participants with a BMI of 27 to 45 kg/m2 (inclusive), including some participants with T2DM. For Part A, after the up to 4-week screening period, the study includes 1 dose and a 12-week safety follow-up after administration. For Part B and Part C, after the up to 4-week screening period, the study includes 12 once-weekly doses and an approximately 11-week safety follow-up after the last administration. Parts A and B will include only participants with overweight or obesity without type 2 diabetes. Part C will include participants with overweight or obesity who also have type 2 diabetes. For Part D, after the up to 4-week screening period, the study includes weekly and monthly (ie, every 4 weeks [QM]) and an approximate 11-week safety follow-up after last administration. For Part E, after the up to 4-week screening period, the study includes multiple dose QW-to-QM and an approximate 11-week safety followup after last administration. For Part G, after the up to 4-week screening period, the study includes multiple dose cohort of QW and QM and an approximate 11-week safety followup after last administration.

03

Conditions studied

  • Obesity and Obesity-related Medical Conditions

Browse trials for

Keywords

  • GLP-1
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males or females aged 18 to 75 years (inclusive) at the time of screening.
  • ≥27.0 kg/m2 and ≤38.0 kg/m2 (inclusive) at Screening for Parts A, B, and C, and ≥30.0 kg/m2 and ≤45.0 kg/m2 (inclusive) at Screening for Parts D and E. Have a BMI ≥27.0 kg/m2 and ≤45.0 kg/m2 (inclusive) at Screening for Parts G.
  • Participants must be in generally stable health, as determined by the investigator based on medical history, physical examination (including vital signs), laboratory evaluations, and (ECG).

    • Participants must have no diseases or clinically significant findings on the physical examination (including vital signs), laboratory evaluations, and electrocardiogram (ECG).
    • Participants in Parts C must not have clinically significant diseases except type 2 diabetes mellitus (T2DM), sleep apnea, well-controlled hypertension, and/or dyslipidemia.
    • Participants in Parts E and G must not have any clinically significant diseases except hypertension, dyslipidemia, and/or a clinical diagnosis of sleep apnea.
  • Willing and able to comply with all scheduled study visits, procedures, and required assessments.
  • Women of must be willing to comply with protocol-specified requirements and must not plan to become pregnant during the study.

Exclusion criteria

Exclusion Criteria:

  • Female who is lactating or who is pregnant according to the pregnancy test at Screening or on Day 1. Unwillingness or inability to comply with protocol-specified requirements.
  • abnormalities in laboratory results in the opinion of the investigator, increase risk or interfere with study participation.
  • Seated blood pressure higher than 160/100 mmHg at the Screening visit or prior to the first study drug administration.
  • Elevated resting pulse greater than 100 beats per minute at Screening visit or prior to the first study drug administration.
  • Estimated (eGFR) \<80 mL/min at the Screening visit.
  • Diagnosis of Type 1 diabetes.
  • For Part A, Part B, Part D, Part E and Part G: Diagnosis of T2DM or (HbA1c) > 6.4% or fasting plasma glucose >126 mg/dL at the Screening visit or history of taking any medications to lower glucose.
  • For Part A, Part B and Part D: Participant reported weight-related comorbidity, including sleep apnea and cardiovascular disease.
  • Use of prohibited prescription or non-prescription medications, supplements, or products within protocol-defined .
  • History or presence of clinically significant gastrointestinal, endocrine, respiratory, renal, hepatic, hematologic, neurologic, cardiovascular, psychiatric, immunologic, or other systemic diseases, except where explicitly permitted by the protocol.
  • Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome, pancreatitis, or pancreatic cancer.
  • History of acute or chronic pancreatitis or pancreatic cancer.
  • Participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration or plans to do so.
  • History of bariatric or weight-loss surgery.
  • Clinically significant psychiatric illness that may interfere with study participation or safety.
  • Screening assessments indicative of moderate to severe depression.
  • History of drug or alcohol abuse or dependence within the past 2 years.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Part A Cohort

    Cohort participants will receive single co-administered ascending dose (SAD) of subcutaneous (SC) MET233 and SC MET097 or matched SC placebo.

    Drug: MET233 and MET097 · Other: Placebo

  • Experimental
    Part B Cohort

    Cohort Participants will receive multiple ascending dose (MAD) of co-administered SC MET233 with SC MET097 or matched SC placebo.

    Drug: MET233 and MET097 · Other: Placebo

  • Experimental
    Part C Cohort

    Cohort Participants will receive multiple doses of SC MET233 co-administered with SC MET097 or matched SC placebo in participants with T2DM.

    Drug: MET233 and MET097 · Other: Placebo

  • Experimental
    Part D Cohort

    Cohort Participants will receive multiple doses of weekly and monthly (ie, every 4 weeks \[QM\]) co-administered SC MET233 with SC MET097, or matched SC placebo in participants with obesity.

    Drug: MET233 and MET097 · Other: Placebo

  • Experimental
    Part E Cohort

    Cohort Participants will receive multiple dose QW-to-QM of SC MET233 co-administered with SC MET097 or matched SC placebo in participants with obesity.

    Drug: MET233 and MET097 · Other: Placebo

  • Experimental
    Part G Cohort

    Cohort Participants will receive multiple dose cohort of QW and QM SC MET097 monotherapy or matched SC placebo in participants with obesity or overweight.

    Other: Placebo · Drug: MET097

Interventions

  • DrugMET233 and MET097

    For subcutaneous administration

  • OtherPlacebo

    Sterile 0.9% (w/v) saline for subcutaneous administration.

  • DrugMET097

    For subcutaneous administration

06

What researchers measure

Primary outcomes

  1. Occurrence of treatment-emergent adverse events (TEAEs)

    For Part A, B, C, D, E and G

    Time frame: Part A (Baseline, Day 85), Part B (Baseline, Day 155), Part C (Baseline, Day 155), Part D (Baseline, Day 218), Part E (Baseline, Day 246), Part G (Baseline, Day 274)

Secondary outcomes

  1. Area under the concentration versus time curve extrapolated to infinity (AUCinf)

    For Part A

    Time frame: Part A (Baseline, Day 85)

  2. Area under the concentration versus time curve during the dosing interval (AUCtau)

    For Part B, C, D, E, and G

    Time frame: Part B (Baseline, Day 155), Part C (Baseline, Day 155), Part D (Baseline, Day 218), Part E (Baseline, Day 246), Part G (Baseline, Day 274)

  3. Minimum observed concentration (Cmin)

    For Part B, C, D, E, and G

    Time frame: Part B (Baseline, Day 155), Part C (Baseline, Day 155), Part D (Baseline, Day 218), Part E (Baseline, Day 246), Part G (Baseline, Day 274)

  4. Maximum observed concentration (Cmax)

    For Part A, B, C, D, E, and G

    Time frame: Part A (Baseline, Day 85), Part B (Baseline, Day 155), Part C (Baseline, Day 155), Part D (Baseline, Day 218), Part E (Baseline, Day 246), Part G (Baseline, Day 274)

  5. Time to maximum observed concentration (Tmax)

    For Part A, B, C, D, E, and G

    Time frame: Part A (Baseline, Day 85), Part B (Baseline, Day 155), Part C (Baseline, Day 155), Part D (Baseline, Day 218), Part E (Baseline, Day 246), Part G (Baseline, Day 274)

  6. Part A: Percent change from baseline in body weight at Day 8

    For Part A

    Time frame: Baseline, Day 8

  7. Part A: Percent change from baseline in body weight at all other postbaseline weight measurements

    For Part A

    Time frame: Part A (Baseline, Day 85)

  8. Part B and Part C: Percent change from baseline in body weight at Day 85

    Time frame: Baseline, Day 85

  9. Part B and Part C: Percent change from baseline in body weight at all other postbaseline weight measurements

    Time frame: Part B and Part C (Baseline, Day 155)

  10. Percent change from baseline in body weight at Day 113

    Part B (Cohorts B4-B6) and Part C

    Time frame: Baseline, Day 113

  11. Percent change from baseline in body weight at all other postbaseline weight measurements

    Part B (Cohorts B4-B6) and Part C

    Time frame: Part B and Part C (Baseline through Day 155)

  12. Percent change from baseline in body weight at Day 113, Day 141 and after QM dosing regimen complete

    For Part D

    Time frame: Part D (Baseline, Day 113, Day 141 and Day 169)

  13. Percent change from baseline in body weight at all other postbaseline weight measurements

    Part D

    Time frame: Part D (Baseline through Day 218)

  14. Percent change from baseline in body weight after QW dosing regimen complete and after QM dosing regimen complete

    For Part E

    Time frame: Part E (Baseline, Day 141 and Day 197)

  15. Percent change from baseline in body weight at all other postbaseline weight measurements

    For Part E

    Time frame: Part E (Baseline through Day 246)

  16. Percent change from baseline in body weight after QW dosing regimen complete and after QM dosing regimen complete

    For Part G

    Time frame: Part G (Baseline, Day 113 and Day 225)

  17. Percent change from baseline in body weight at all other postbaseline weight measurements

    For Part G

    Time frame: Part G (Baseline through Day 274)

07

Study locations

1 site
  • Altasciences Clinical Los Angeles, Inc.
    Cypress, California 90630, United States
08

References and documents

Publications

  • Bailey CJ, Flatt PR, Conlon JM. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides. 2026 Mar;196:171480. doi: 10.1016/j.peptides.2026.171480. Epub 2026 Feb 24. PubMed 41747885 ↗

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Sep 2026, 18 months.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 11, 2025
StartActual
Mar 6, 2025
Primary completionActual
Sep 29, 2026
CompletionActual
Sep 29, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 2, 2026
Primary completion
Sep 15, 2026→Sep 29, 2026 (actual)
Nov 2, 2026
Study completion
Sep 15, 2026→Sep 29, 2026 (actual)
Nov 2, 2026
Enrollment
381 (estimated)→201 (actual)
Nov 2, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedPercent change from baseline in body weight at Day 106113Time frame: Baseline, Day 106 → Baseline, Day 113
  • EditedPercent change from baseline in body weight at Day 113, Day 141 and after QM dosing regimen completeTime frame: Part D (Baseline, Day 113 and Day 169) → Part D (Baseline, Day 113, Day 141 and Day 169)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Completed
    Primary completion Sep 15, 2026→Sep 29, 2026 (now actual)
    Study completion Sep 15, 2026→Sep 29, 2026 (now actual)
    Enrollment 381 (estimated)→201 (actual)
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedPercent change from baseline in body weight at Day 106113Time frame: Baseline, Day 106 → Baseline, Day 113
    • EditedPercent change from baseline in body weight at Day 113, Day 141 and after QM dosing regimen completeTime frame: Part D (Baseline, Day 113 and Day 169) → Part D (Baseline, Day 113, Day 141 and Day 169)
    + 7 other changes: identifiers, verification date, registry dates, conditions, contact details, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06924320
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
Mar 6, 2025
Primary completion
Sep 29, 2026
Completion
Sep 29, 2026
Last update
Nov 2, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berobenatide

Start the discussion